Clinical Trial Update: A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase Ib/II study investigating AK104 and AK117 with or without chemotherapy in advanced malignant tumors; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Tumors

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK117 (AK117)

Snippet

Sponsor: Akeso | Conditions: Advanced Malignant Tumors | Phase 1, Phase 2 | Status: UNKNOWN